Cerevel Therapeutics Holdings, Inc. (CERE) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Cambridge, MA, 미국. 현재 CEO는 Ronald C. Renaud Jr.,.
CERE 을(를) 보유 IPO 날짜 2020-07-30, 355 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $8.19B.
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases including schizophrenia, epilepsy, Parkinson's disease, and psychiatric disorders. The company's pipeline includes several lead programs in clinical development, such as emraclidine for schizophrenia, Darigabat for drug-resistant epilepsy and anxiety, and Tavapadon for Parkinson's disease, alongside multiple earlier-stage candidates targeting conditions like dementia-related apathy, substance use disorder, and major depressive disorder. Founded in 2018 and headquartered in Cambridge, Massachusetts, Cerevel leverages multiple molecular mechanisms and receptor targets to address critical unmet needs in central nervous system disorders.
